BiologicalDrug
Incomplete Freund's adjuvant clinical trials
Also written IFA and ISA-51.
Keep track of what changes. Save the incomplete Freund's adjuvant studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
15 studies that test it; most in 2004 (3)
| Year | Studies |
|---|---|
| 1996 | 1 |
| 1998 | 1 |
| 1999 | 1 |
| 2001 | 1 |
| 2003 | 1 |
| 2004 | 3 |
| 2005 | 1 |
| 2006 | 1 |
| 2008 | 1 |
| 2011 | 1 |
| 2019 | 1 |
| 2023 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 0 · Other 15
National Cancer Institute (NCI) (5) · University of Virginia (3) · University of Southern California (2) · Roswell Park Cancer Institute (1) · Ethiopian Public Health Institute (1) · University of California, Davis (1) · Craig L Slingluff, Jr (1) · ETH Zurich (1)
Often tested with
Tested in the same studies.
Granulocyte-Macrophage Colony-Stimulating Factor (2) · Octreotide (1) · Sargramostim (1) · SVN53-67/M57-KLH peptide vaccine (1) · GP-100 antigen (1) · MART-1 Antigen (1) · Multi-epitope Melanoma Peptide Vaccine (1) · Tetanus toxoid helper peptide (1)
Studies
Open first, then newest update. How each study uses incomplete Freund's adjuvant is read from its arms, and is right about nine times in ten.
Testing it · 15
- Iron Absorption From IFA and MMS Supplements in Kenyan Women During the Second Trimester of PregnancyRecruitingNot applicableETH ZurichNCT07435766Written as IFA with 60 mg iron
- Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine TumorsCompletedPhase 1Roswell Park Cancer InstituteNCT03879694Written as Incomplete Freund's Adjuvant
- The Effect of Multiple Micronutrient Supplements in Reducing Anemia in Women of Reproductive AgeCompletedNot applicableEthiopian Public Health InstituteNCT05682261Written as IFA
- Vaccine Therapy in Treating Patients With Metastatic Melanoma of the EyeCompletedPhase 2National Cancer Institute (NCI)NCT00020475Written as Montanide ISA-51
- Effectiveness of LNS and MNP Supplements to Prevent Malnutrition in Women and Their Children in BangladeshCompletedNot applicableUniversity of California, DavisNCT01715038Written as IFA
- Vaccine Therapy in Treating Patients With Advanced MelanomaCompletedPhase 1Craig L Slingluff, JrNCT00705640Written as incomplete Freund's adjuvant
- Vaccine Therapy in Treating Patients With Metastatic MelanomaCompletedPhase 1University of VirginiaNCT00003224Written as IFA (incomplete Freund's adjuvant)
- Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV MelanomaCompletedPhase 1/2University of VirginiaNCT00089219Written as IFA
- Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With Renal Cell CarcinomaTerminatedPhase 2National Cancer Institute (NCI)NCT00001703Written as incomplete Freund's adjuvant
- Vaccine Therapy in Treating Patients With Stage IIC-IV MelanomaCompletedPhase 2University of Southern CaliforniaNCT00085189Written as incomplete Freund's adjuvant
- Continuation Booster Trial After a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With or Without GM-CSF for Patients With MelanomaTerminatedPhase 2University of Southern CaliforniaNCT00184067Written as Montanide ISA 51
- Vaccine Therapy in Treating Patients With Recurrent Prostate CancerCompletedPhase 2National Cancer Institute (NCI)NCT00109811Written as incomplete Freund's adjuvant
- Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic MelanomaCompletedPhase 2National Cancer Institute (NCI)NCT00001832Written as Montanide ISA-51
- Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk MelanomaCompletedPhase 2National Cancer Institute (NCI)NCT00273910Written as Montanide ISA-51
- Evaluation of the Effects of Local Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Adjuvant Administration on Dendritic Cells in Skin of Melanoma Patients and in Sentinel Lymph Nodes: MEL38CompletedNot applicableUniversity of VirginiaNCT00912574Written as Montanide ISA-51
Given in every arm · 17 — incomplete Freund's adjuvant is usual care beside what is tested
- Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine CarcinomasNot yet recruitingPhase 2Roswell Park Cancer InstituteNCT06202066Written as Incomplete Freund''s Adjuvant
- SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance TherapyActive, not recruitingPhase 1Roswell Park Cancer InstituteNCT02334865Written as Incomplete Freund's Adjuvant
- Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First RecurrenceCompletedPhase 2David PeereboomNCT04013672Written as Montanide ISA 51
- Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV MelanomaCompletedPhase 1/2Craig L Slingluff, JrNCT03617328Written as Montanide ISA-51
- Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of MelanomaTerminatedPhase 1/2Craig L Slingluff, JrNCT02425306Written as Montanide ISA-51
- Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic MelanomaCompletedPhase 2Eastern Cooperative Oncology GroupNCT00071981Written as incomplete Freund's adjuvant
- Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal CancerCompletedPhase 1Roswell Park Cancer InstituteNCT01673217Written as incomplete Freund's adjuvant
- Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV MelanomaCompletedPhase 1/2Craig L Slingluff, JrNCT00118274Written as incomplete Freund's adjuvant
- Immunization of Disease-Free Melanoma Patients With Different HLA-A2 PeptidesTerminatedPhase 1/2Cliniques universitaires Saint-Luc- Université Catholique de LouvainNCT00365937Written as Montanide ISA51
- Peptide-specific Vaccination in HLA-A*02 Positive Patients With Biochemical Recurrence After Radical ProstatectomyStatus unknownPhase 1/2University Hospital TuebingenNCT02452307Written as Montanide ISA-51
- Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or MesotheliomaCompletedPhase 1Memorial Sloan Kettering Cancer CenterNCT00398138Written as incomplete Freund's adjuvant
- Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma PatientsTerminatedPhase 2National Cancer Institute (NCI)NCT00706992Written as incomplete Freund's adjuvant
- Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for MelanomaCompletedPhase 2National Cancer Institute (NCI)NCT00089063Written as incomplete Freund's adjuvant
- Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV MelanomaCompletedPhase 2University of VirginiaNCT00003222Written as incomplete Freund's adjuvant
- Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic MelanomaTerminatedPhase 2National Cancer Institute (NCI)NCT00303836Written as incomplete Freund's adjuvant
- Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant MelanomaCompletedNot applicableNational Cancer Institute (NCI)NCT00006243Written as incomplete Freund's adjuvant
- Peptide Vaccination for Patients at High Risk for Recurrent MelanomaCompletedPhase 2National Cancer Institute (NCI)NCT00059475Written as Montanide ISA 51
As the comparator · 5 — what is tested is compared with incomplete Freund's adjuvant
- The MOM-CARE Trial : Evaluating Antenatal and Postnatal MMSPlus for Improved Infant Birth and Growth OutcomesRecruitingPhase 3Aga Khan UniversityNCT07029282Written as IFA
- Supplementing Maternal and Infant Diet With High-energy, Micronutrient Fortified Lipid-based Nutrient Supplements (LNS)Active, not recruitingPhase 3Tampere UniversityNCT01239693Written as IFA
- Calcium Aspirin Multiple Micronutrients (CAMMS) to Reduce Preterm BirthWithdrawnPhase 3Johns Hopkins Bloomberg School of Public HealthNCT05612984Written as Iron-folic Acid
- Adjuvant Antigen Specific Immunotherapy in Patients With Advanced Renal Cell Carcinoma Using Tumor Associated PeptidesStatus unknownPhase 1/2University Hospital TuebingenNCT02429440Written as Montanide ISA-51
- Prevention of Intrauterine Growth Retardation in Hounde District, Burkina FasoCompletedPhase 4Institute of Tropical Medicine, BelgiumNCT00642408Written as IFA
Codes
What other systems call incomplete Freund's adjuvant · ClinicalTrials.gg INT018575
- UNII (FDA) Y9DQK7DB5UINCOMPLETE FREUND'S ADJUVANTOne source FDA
- NCI Thesaurus C1573Incomplete Freund's AdjuvantOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | Y9DQK7DB5U | INCOMPLETE FREUND'S ADJUVANT | One source FDA |
| NCI Thesaurus | C1573 | Incomplete Freund's Adjuvant | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.